Edward F. Patz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edward F. Patz has a total of 639 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth B. Gottlin
Department of Radiology, Duke University Medical Center, Durham, North Carolina, United States of America
66 shared publications - Michael J. Campa
Grid Therapeutics, Durham, North Carolina
57 shared publications - Ryan T. Bushey
Grid Therapeutics, Durham, North Carolina
53 shared publications - You-Wen He
Duke University School of Medicine, Durham, USA
43 shared publications - Ruchi Saxena
Department of Integrative Immunobiology, Duke University School of Medicine, Durham, USA
41 shared publications - Abbie S. Ireland
Department of Pharmacology and Cancer Biology, Duke University, Durham, USA
27 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (44) , 4777-4790
Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing
Characterizing the genealogy of tumor cells and their population dynamics is central to our understanding of the evolution of cancer. While direct monitoring of the tumor evolutionary process is impractical, we leverage advances in phylogenetics and phylodynamics to explore the evolutionary dynamics of non-small cell lung cancer (NSCLC) using single-cell whole exome sequencing data from 351 tumor cells across 11 NSCLC patients, predominantly focusing on the primary tumors and early stages of NSCLC. Our results reveal distinct phylogenetic tree shapes and evolutionary trajectories across different stages of NSCLC evolution. However, this intricate and multi-phase evolutionary process cannot be fully elucidated by current tumor models. Herein, we hypothesize that tumors progress through the following phases: (1) an initial rapid expansion through Big Bang-like growth, (2) a prolonged plateau period of non-progression with possible accumulation of neutral substitutions, (3) a subsequent phase where adaptive substitutions accumulate gradually, (4) a bottleneck event where selectively advantageous subclones acquire invasive capabilities (characterized by a pattern of punctuated evolution), and, potentially, a rapid expansion leading to metastasis. This work highlights the use of single-cell phylogenetics and phylodynamics for interpreting the evolution of NSCLC, with potential in predicting cancer progression, resistance mechanisms, and treatment response.
- 24 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (44) , 4777-4790
Open AccessPhylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing
Characterizing the genealogy of tumor cells and their population dynamics is central to our understanding of the evolution of cancer. While direct monitoring of the tumor evolutionary process is impractical, we leverage advances in phylogenetics and phylodynamics to explore the evolutionary dynamics of non-small cell lung cancer (NSCLC) using single-cell whole exome sequencing data from 351 tumor cells across 11 NSCLC patients, predominantly focusing on the primary tumors and early stages of NSCLC. Our results reveal distinct phylogenetic tree shapes and evolutionary trajectories across different stages of NSCLC evolution. However, this intricate and multi-phase evolutionary process cannot be fully elucidated by current tumor models. Herein, we hypothesize that tumors progress through the following phases: (1) an initial rapid expansion through Big Bang-like growth, (2) a prolonged plateau period of non-progression with possible accumulation of neutral substitutions, (3) a subsequent phase where adaptive substitutions accumulate gradually, (4) a bottleneck event where selectively advantageous subclones acquire invasive capabilities (characterized by a pattern of punctuated evolution), and, potentially, a rapid expansion leading to metastasis. This work highlights the use of single-cell phylogenetics and phylodynamics for interpreting the evolution of NSCLC, with potential in predicting cancer progression, resistance mechanisms, and treatment response.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
NGFR + cells give rise to KRT13+ hillock-like cells, related to Fig. 5.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
NGFR + cells give rise to KRT13+ hillock-like cells, related to Fig. 5.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Identifying candidate regulators of the hillock cell state and KLF4 as a regulator of KRT13, related to Fig. 6.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Identifying candidate regulators of the hillock cell state and KLF4 as a regulator of KRT13, related to Fig. 6.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
KLF4 regulates the KRT13+ hillock-like-state, related to Fig. 7.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
KLF4 regulates the KRT13+ hillock-like-state, related to Fig. 7.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
KLF4 regulates resistance to cisplatin but not paclitaxel, related to Fig. 7.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
KLF4 regulates resistance to cisplatin but not paclitaxel, related to Fig. 7.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S9 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Hillock-like cells are present in squamous tumors of the esophagus and head and neck, related to Fig. 8.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S9 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Hillock-like cells are present in squamous tumors of the esophagus and head and neck, related to Fig. 8.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Hillock score genes for mouse and human, related to Fig. 3
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Hillock score genes for mouse and human, related to Fig. 3
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Immune cell population correlation to the hillock-like cell state by CIBERSORT deconvolution, related to Fig. 4
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Immune cell population correlation to the hillock-like cell state by CIBERSORT deconvolution, related to Fig. 4
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Differentially expressed genes in hillock-like tumor organoid cells derived from scRNA-seq data, related to Supplementary Fig. S5
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
Differentially expressed genes in hillock-like tumor organoid cells derived from scRNA-seq data, related to Supplementary Fig. S5
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
ENCODE and ChEA Consensus TFs from ChIP-X from mouse and human hillock-like and basal-like cells, related to Supplementary Fig. S6
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from KLF4 Promotes a KRT13+ Hillock-Like State in Lung Squamous Cell Carcinoma
ENCODE and ChEA Consensus TFs from ChIP-X from mouse and human hillock-like and basal-like cells, related to Supplementary Fig. S6